RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > A Review of the Pharmacovigilance Programme of India

A Review of the Pharmacovigilance Programme of India

Posted 01 September 2011 | By

Over the past decade, India has been steadily evolving into one of the world's most important pharmaceutical centers for clinical trials and research and development. With success has come the burden of growing pressure on the Indian government to address concerns related to establishing a reliable drug safety framework.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe